WUXIHYBRID Trademark

Trademark Overview

On Monday, April 12, 2021, a trademark application was filed for WUXIHYBRID with the United States Patent and Trademark Office. The USPTO has given the WUXIHYBRID trademark a serial number of 90638798. The federal status of this trademark filing is REGISTERED as of Tuesday, May 23, 2023. This trademark is owned by WuXi Biologics Ireland Limited. The WUXIHYBRID trademark is filed in the Treatment & Processing of Materials Services and Computer & Software Services & Scientific Services categories with the following description:

Custom manufacture of pharmaceuticals, biopharmaceuticals, nutraceuticals, vitamins by pharmaceutical compounders

Product development for others; Pharmaceutical drug development services; Scientific research and development; pharmaceutical research services; Research and development of new products; Consulting services in the field of pharmaceutical technology development; Biochemical research and analysis; Research in the field of biomedical science; Pharmaceutical preparations and medicines development; Research and development services in the field of antibodies
wuxihybrid

General Information

Serial Number90638798
Word MarkWUXIHYBRID
Filing DateMonday, April 12, 2021
Status700 - REGISTERED
Status DateTuesday, May 23, 2023
Registration Number7062819
Registration DateTuesday, May 23, 2023
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 19, 2022

Trademark Statements

Goods and ServicesCustom manufacture of pharmaceuticals, biopharmaceuticals, nutraceuticals, vitamins by pharmaceutical compounders
Goods and ServicesProduct development for others; Pharmaceutical drug development services; Scientific research and development; pharmaceutical research services; Research and development of new products; Consulting services in the field of pharmaceutical technology development; Biochemical research and analysis; Research in the field of biomedical science; Pharmaceutical preparations and medicines development; Research and development services in the field of antibodies

Classification Information

International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateMonday, July 19, 2021
Primary Code040
First Use Anywhere DateWednesday, September 30, 2020
First Use In Commerce DateWednesday, September 30, 2020
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, July 19, 2021
Primary Code042
First Use Anywhere DateWednesday, September 30, 2020
First Use In Commerce DateWednesday, September 30, 2020

Trademark Owner History

Party NameWuXi Biologics Ireland Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressDUNDALK, COUNTY LOUTH A91X56F
IE
Party NameWuXi Biologics Ireland Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressDUNDALK, COUNTY LOUTH A91X56F
IE
Party NameWuXi Biologics Ireland Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressDUNDALK, COUNTY LOUTH A91X56F
IE

Trademark Events

Event DateEvent Description
Tuesday, May 23, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, May 23, 2023REGISTERED-PRINCIPAL REGISTER
Tuesday, April 18, 2023NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Monday, April 17, 2023ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Saturday, March 25, 2023STATEMENT OF USE PROCESSING COMPLETE
Monday, March 13, 2023USE AMENDMENT FILED
Saturday, March 25, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, March 13, 2023TEAS STATEMENT OF USE RECEIVED
Tuesday, September 13, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 19, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 19, 2022PUBLISHED FOR OPPOSITION
Wednesday, June 29, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 17, 2022WITHDRAWN FROM PUB - OG REVIEW QUERY
Tuesday, May 3, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, May 3, 2022EXAMINER'S AMENDMENT ENTERED
Tuesday, May 3, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, May 3, 2022EXAMINERS AMENDMENT E-MAILED
Tuesday, May 3, 2022EXAMINERS AMENDMENT -WRITTEN
Monday, May 2, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, May 2, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, May 2, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, February 9, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, February 9, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, February 9, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sunday, November 21, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sunday, November 21, 2021NON-FINAL ACTION E-MAILED
Sunday, November 21, 2021NON-FINAL ACTION WRITTEN
Wednesday, November 17, 2021ASSIGNED TO EXAMINER
Monday, August 2, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, August 2, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, August 2, 2021TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Monday, August 2, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, August 2, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, August 2, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, July 19, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, May 4, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, May 4, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, May 4, 2021TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Tuesday, May 4, 2021TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Tuesday, May 4, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, May 4, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, May 4, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, April 15, 2021NEW APPLICATION ENTERED

Related Keywords

wuxihybrid development research pharmaceutical services field biochemical technology analysis consulting biomedical